Curetis Expands Supervisory and Medical Advisory Boards
(Thomson Reuters ONE) -
Curetis /
Curetis Expands Supervisory and Medical Advisory Boards
. Processed and transmitted by Nasdaq Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
Curetis Expands Supervisory and Medical Advisory Boards
- Dr. Nils Clausnitzer nominated for election to Supervisory Board; Dr. Melissa
Miller appointed to Medical Advisory Board
Amsterdam, the Netherlands and Holzgerlingen, Germany, April 12, 2017 -- Curetis
N.V. (the "Company" and, together with Curetis GmbH, "Curetis"), a developer of
next-level molecular diagnostic solutions, today announced that it has nominated
Dr. med. Nils Clausnitzer, MBA, for election to its Supervisory Board. The
election will take place at the upcoming General Shareholder Meeting on June
23, 2017. In addition, Dr. Melissa Miller has joined Curetis' Medical Advisory
Board (MAB).
Dr. Clausnitzer is expected to significantly strengthen Curetis' commercial MDx
expertise at the board level. Since January 2016, Dr. Clausnitzer has been
Senior Vice President and President, EMEA-APAC Lab and Distribution Services of
VWR International llc./ VWR GmbH. From 2013 - 2015, he was President and Head of
Commercial Operations, EMEA, and from 2010 - 2013 Vice President, Head of
Commercial Operations MDx, Europe with Qiagen. Previously, Dr. Clausnitzer was
Managing Director and General Manager of Abbott Diagnostics Germany and held
several leadership functions with increasing responsibilities at Olympus Germany
GmbH, most recently as Deputy Managing Director, General Manager Medical Service
DACH. He started his professional career in 1998 in the Department for
Diagnostic Radiology at University Hospital Eppendorf, Hamburg. Dr. Clausnitzer
holds an MBA degree from the Open University, Milton Keynes, UK.
Dr. Melissa Miller is Professor of Pathology and Laboratory Medicine and
Director, Clinical Molecular Microbiology Laboratory, as well as Associate
Director, Clinical Microbiology Laboratory, at the University of North Carolina
at Chapel Hill School of Medicine in the U.S.
In addition, she is the current chair of the ASM Committee on Laboratory
Practices, the co-chair of the Pan American Society for Clinical Virology
Professional Practices Committee, and a fellow of the American Academy of
Microbiology.
"We are very pleased about adding further commercial industry and clinical
expertise to our Supervisory and Medical Advisory Boards," said Dr. Oliver
Schacht, CEO of Curetis. "Both Dr. Clausnitzer and Dr. Miller have a strong
track record in infectious disease diagnostics, either from a commercial or a
clinical angle and we look forward to working with them to further advance
Curetis as a leading MDx company."
Disclaimer
CAUTION - Investigational device. Limited by Federal (or United States) law to
investigational use. The information contained in this communication does not
constitute nor imply an offer to sell or transfer any product, and no product
based on the Curetis Unyvero technology is currently available for sale in the
United States of America or Canada. The analytical and clinical performance
characteristics of any Curetis Unyvero product which may be sold at some future
point in time in the U.S. have not yet been established.
###
About Curetis
Founded in 2007, Curetis is a molecular diagnostics company which focuses on the
development and commercialization of reliable, fast and cost-effective products
for diagnosing severe infectious diseases. The diagnostic solutions of Curetis
enable rapid multi-parameter pathogen and antibiotic resistance marker detection
in only a few hours, a process that today can take up to days or even weeks with
other techniques.
To date, Curetis has raised EUR 44.3 million in an IPO on Euronext Amsterdam and
Euronext Brussels and private equity funds of over EUR 63.5 million.
Furthermore, Curetis has entered into a debt financing facility with EIB for up
to EUR 25 million. The company is based in Holzgerlingen near Stuttgart,
Germany. Curetis collaborates with Heraeus Medical, pharmaceutical companies,
and has entered into several international distribution agreements covering many
countries across Europe, the Middle East and Asia.
In 2017, Curetis established Ares Genetics GmbH, a wholly-owned subsidiary of
Curetis GmbH in Vienna, Austria. Ares Genetics is dedicated to maximizing the
R&D and related scientific and business opportunities of the GEAR assets
acquired in 2016 for the entire Curetis Group.
For further information, please visit www.curetis.com.
Legal Disclaimer
This document constitutes neither an offer to buy nor to subscribe securities
and neither this document nor any part of it should form the basis of any
investment decision in Curetis.
The information contained in this press release has been carefully prepared.
However, Curetis bears and assumes no liability of whatever kind for the
correctness and completeness of the information provided herein. Curetis does
not assume an obligation of whatever kind to update or correct information
contained in this press release whether as a result of new information, future
events or for other reasons.
This press release includes statements that are, or may be deemed to be,
"forward-looking statements". These forward-looking statements can be identified
by the use of forward-looking terminology, including the terms "believes",
"estimates", "anticipates", "expects", "intends", "may", "will", or "should",
and include statements Curetis makes concerning the intended results of its
strategy. By their nature, forward-looking statements involve risks and
uncertainties and readers are cautioned that any such forward-looking statements
are not guarantees of future performance. Curetis' actual results may differ
materially from those predicted by the forward-looking statements. Curetis
undertakes no obligation to publicly update or revise forward-looking
statements, except as may be required by law.
Contact details
Curetis AG
Max-Eyth-Str. 42
71088 Holzgerlingen, Germany
Tel. +49 7031 49195-10
pr(at)curetis.com or ir(at)curetis.com
www.curetis.com - www.unyvero.com
International Media & Investor Inquiries
akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
info((at))akampion.com
Tel. +49 40 88 16 59 64
Tel. +49 30 23 63 27 68
U.S. Media & Investor Inquiries
The Ruth Group
Lee Roth
lroth(at)theruthgroup.com
Tel. +1 646 536 7012
Curetis_Logo:
http://hugin.info/171382/R/2095692/792750.jpg
20170412_Curetis_PR_EN_01:
http://hugin.info/171382/R/2095692/792749.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Curetis via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 12.04.2017 - 07:18 Uhr
Sprache: Deutsch
News-ID 535878
Anzahl Zeichen: 7963
contact information:
Town:
Holzgerlingen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 299 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Curetis Expands Supervisory and Medical Advisory Boards"
steht unter der journalistisch-redaktionellen Verantwortung von
Curetis (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
